Latest Board Renewal News

Alliance Aviation Services has reported a robust half-year performance with a 9.5% increase in statutory profit before tax and record flight hours, underpinned by fleet expansion and strong wet lease demand.

Challenger Gold has secured a binding toll processing agreement to fast-track production at its Hualilan Gold Project in Argentina, while also reporting promising drilling results from its Colorado V project in Ecuador and completing a strategic capital raise.

Cosmo Metals has made significant strides in its exploration programs at the Kanowna Gold Project and Yamarna Region, supported by a recent $500,000 capital raise via convertible notes. The company is strategically evaluating project opportunities to maximise stakeholder value.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Earth's Energy Limited reports promising progress in its Paralana and Flinders West geothermal projects, confirming new development zones and initiating joint venture discussions, while maintaining a solid cash position.

Lindian Resources has secured a US$50 million non-binding funding term sheet with Gerald Group, progressing its Kangankunde Rare Earths Project, while also signing a 10-year lease for its Woula bauxite project in Guinea and navigating significant board changes.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.